A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer.

Autor: Avanzino BC; Teneobio, Inc, Newark, CA, United States.; Oncology Research, Amgen Inc., Newark, CA, USA., Prabhakar K; Teneobio, Inc, Newark, CA, United States.; Oncology Research, Amgen Inc., Newark, CA, USA., Dalvi P; Teneobio, Inc, Newark, CA, United States.; Oncology Research, Amgen Inc., Newark, CA, USA., Hartstein S; Teneobio, Inc, Newark, CA, United States.; Therapeutic Discovery, Amgen Inc., Newark, CA, USA., Kehm H; Teneobio, Inc, Newark, CA, United States., Balasubramani A; Teneobio, Inc, Newark, CA, United States.; Therapeutic Discovery, Amgen Inc., Newark, CA, USA., Boudreau AA; Teneobio, Inc, Newark, CA, United States., Buelow B; Teneobio, Inc, Newark, CA, United States., Chang K; Teneobio, Inc, Newark, CA, United States., Davison LM; Teneobio, Inc, Newark, CA, United States., Iyer S; Teneobio, Inc, Newark, CA, United States., Kalwit V; Teneobio, Inc, Newark, CA, United States.; Oncology Research, Amgen Inc., Newark, CA, USA., Lewis Wilson K; Translational Safety & Bioanalytical Sciences, Amgen Inc., South San Francisco, CA, USA., Malik-Chaudhry HK; Teneobio, Inc, Newark, CA, United States.; Therapeutic Discovery, Amgen Inc., Newark, CA, USA., Pierson W; Division of Gynecologic Oncology, University of California, San Francisco, CA, USA.; University of Rochester School of Medicine and Dentistry, Rochester, NY, USA., Pineda G; Division of Gynecologic Oncology, University of California, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Rangaswamy US; Teneobio, Inc, Newark, CA, United States.; Oncology Research, Amgen Inc., Newark, CA, USA., Saiganesh S; Teneobio, Inc, Newark, CA, United States.; Oncology Research, Amgen Inc., Newark, CA, USA., Schellenberger U; Teneobio, Inc, Newark, CA, United States., Ugamraj HS; Teneobio, Inc, Newark, CA, United States.; Process Development, Amgen Inc., Newark, CA, USA., Yabut RD; Translational Safety & Bioanalytical Sciences, Amgen Inc., South San Francisco, CA, USA., Buelow R; Teneobio, Inc, Newark, CA, United States., Chapman J; Division of Gynecologic Oncology, University of California, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Trinklein ND; Teneobio, Inc, Newark, CA, United States., Harris KE; Teneobio, Inc, Newark, CA, United States.; Oncology Research, Amgen Inc., Newark, CA, USA.

Publikováno v: Oncoimmunology [Oncoimmunology] 2022 Aug 20; Vol. 11 (1), pp. 2113697. Date of Electronic Publication: 2022 Aug 20 (Print Publication: 2022).